Metastatic cancer is responsible for the vast majority of cancer deaths, but our limited understanding of how metastasis begins makes finding ways to stop it hugely challenging. A new study may provide some insight, however.
Researchers at Stanford University School of Medicine with the National Cancer Institute (NCI) have identified another cancer-surface molecule, CD22, and begun trials on B-cell acute lymphoblastic leukemia (ALL) patients using an immuno-oncology approach similar to CAR-T. In the Phase I trial, 15 of the 21 patients who had previously relapsed or did not respond to anti-CD19 CAR-T, were treated with an anti-CD22 CAR-T therapy. Ten of the 15 patients had already received treatment for CD19-targeted treatment.
Authorities in the city of Nanjing, the capital of China’s Jiangsu province, announced at the end of October that they would sequence the genes of 1 million individuals to build a genetic database of Chinese residents. This project is part of the National Health and Medicine Big Data Nanjing Center, a new data storage facility under construction in the region.
Conventional doctors have considered chemotherapy treatment and radiation to be the standard of care for so long, they’ve lost sight of the fact that these treatments are causing cancer − not curing it. Did they somehow miss the fact that these super toxic cancer therapies could be the reason for their repeat customers?
Cancer cells are relentless, possessing the vexatious ability to develop resistance to current therapies and making the disease hugely challenging to treat. However, an exciting new study may have identified cancer's weak spot; the discovery has already led to the near-eradication of the disease in cell cultures.
New research suggests that men with abnormally low levels of testosterone are less likely to develop prostate cancer in their lifetime. The new study was carried out by scientists at the University of Oxford in the United Kingdom, and the findings were presented at the National Cancer Research Institute (NCRI) Cancer Conference, held in Liverpool, U.K.
Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the world's more diverse populations, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and the Keck School of Medicine of the University of Southern California (USC).
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.